Maxim downgraded NeuroSense (NRSN) to Hold from Buy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRSN:
- NeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment
- NeuroSense concludes Type C meeting with FDA for PrimeC treatment
- NeuroSense files to sell 6.6M ordinary shares for holders
- NeuroSense’s PrimeC Shows Promise in ALS Treatment
- NeuroSense announces ‘positive’ results from the PARADIGM study